Biochemistry of Alzheimer's disease
The biochemistry of Alzheimer's disease (AD), one of the most common causes of adult dementia, is not yet very well understood. AD has been identified as a protein misfolding disease due to the accumulation of abnormally folded amyloid beta protein in the brains of Alzheimer's patients. Amyloid beta, also written Aβ, is a short peptide that is an abnormal proteolytic byproduct of the transmembrane protein amyloid precursor protein (APP), whose function is unclear but thought to be involved in neuronal development. The presenilins are components of proteolytic complex involved in APP processing and degradation.
Amyloid beta monomers are soluble and contain short regions of beta sheet and polyproline II helix secondary structures in solution, though they are largely alpha helical in membranes; however, at sufficiently high concentration, they undergo a dramatic conformational change to form a beta sheet-rich tertiary structure that aggregates to form amyloid fibrils. These fibrils deposit outside neurons in dense formations known as senile plaques or neuritic plaques, in less dense aggregates as diffuse plaques, and sometimes in the walls of small blood vessels in the brain in a process called amyloid angiopathy or congophilic angiopathy.
AD is also considered a tauopathy due to abnormal aggregation of the tau protein, a microtubule-associated protein expressed in neurons that normally acts to stabilize microtubules in the cell cytoskeleton. Like most microtubule-associated proteins, tau is normally regulated by phosphorylation; however, in AD patients, hyperphosphorylated tau accumulates as paired helical filaments that in turn aggregate into masses inside nerve cell bodies known as neurofibrillary tangles and as dystrophic neurites associated with amyloid plaques. Although little is known about the process of filament assembly, it has recently been shown that a depletion of a prolyl isomerase protein in the parvulin family accelerates the accumulation of abnormal tau.
Neuroinflammation is also involved in the complex cascade leading to AD pathology and symptoms. Considerable pathological and clinical evidence documents immunological changes associated with AD, including increased pro-inflammatory cytokine concentrations in the blood and cerebrospinal fluid. Whether these changes may be a cause or consequence of AD remains to be fully understood, but inflammation within the brain, including increased reactivity of the resident microglia towards amyloid deposits, has been implicated in the pathogenesis and progression of AD.
At a macroscopic level, AD is characterized by loss of neurons and synapses in the cerebral cortex and certain subcortical regions. This results in gross atrophy of the affected regions, including degeneration in the temporal lobe and parietal lobe, and parts of the frontal cortex and cingulate gyrus.
Both amyloid plaques and neurofibrillary tangles are clearly visible by microscopy in AD brains. Plaques are dense, mostly insoluble deposits of protein and cellular material outside and around neurons. Tangles are insoluble twisted fibers that build up inside the nerve cell. Though many older people develop some plaques and tangles, the brains of AD patients have them to a much greater extent and in different brain locations.
Although AD shares pathophysiological mechanisms with prion diseases, it should be noted that AD is not transmissible like prion diseases. Amyloid-beta, also written Aβ, is a short peptide that is a proteolytic byproduct of the transmembrane protein amyloid precursor protein (APP), whose function is unclear but thought to be involved in neuronal development. The presenilins are components of a proteolytic complex involved in APP processing and degradation. Although amyloid beta monomers are harmless, they undergo a dramatic conformational change at sufficiently high concentration to form a beta sheet-rich tertiary structure that aggregates to form amyloid fibrils that deposit outside neurons in dense formations known as senile plaques or neuritic plaques, in less dense aggregates as diffuse plaques, and sometimes in the walls of small blood vessels in the brain in a process called amyloid angiopathy or congophilic angiopathy.
AD is also considered a tauopathy due to abnormal aggregation of the tau protein, a microtubule-associated protein expressed in neurons that normally acts to stabilize microtubules in the cell cytoskeleton. Like most microtubule-associated proteins, tau is normally regulated by phosphorylation; however, in AD patients, hyperphosphorylated tau accumulates as paired helical filaments that in turn aggregate into masses inside nerve cell bodies known as neurofibrillary tangles and as dystrophic neurites associated with amyloid plaques.
Levels of the neurotransmitter acetylcholine are reduced. Levels of the neurotransmitters serotonin, norepinephrine, and somatostatin are also often reduced. Glutamate levels are usually elevated.
Although the gross histological features of AD in the brain are well characterized, three major hypotheses have been advanced regarding the primary cause. The oldest hypothesis suggests that deficiency in cholinergic signaling initiates the progression of the disease. Two alternative misfolding hypotheses instead suggest that either tau protein or amyloid beta initiates the cascade. While researchers have not identified a clear causative pathway originating from any of the three molecular hypotheses to explain the gross anatomical changes observed in advanced AD, variants of the amyloid beta hypothesis of molecular initiation have become dominant among the three possibilities.
The oldest hypothesis is the "cholinergic hypothesis". It states that Alzheimer's begins as a deficiency in the production of acetylcholine, a vital neurotransmitter. Much early therapeutic research was based on this hypothesis, including restoration of the "cholinergic nuclei". The possibility of cell-replacement therapy was investigated on the basis of this hypothesis. All of the first-generation anti-Alzheimer's medications are based on this hypothesis and work to preserve acetylcholine by inhibiting acetylcholinesterases (enzymes that break down acetylcholine). These medications, though sometimes beneficial, have not led to a cure. In all cases, they have served to only treat symptoms of the disease and have neither halted nor reversed it. These results and other research have led to the conclusion that acetylcholine deficiencies may not be directly causal, but are a result of widespread brain tissue damage, damage so widespread that cell-replacement therapies are likely to be impractical. More recently, cholinergic effects have been proposed as a potential causative agent for the formation of plaques and tangles leading to generalized neuroinflammation.
More recent hypotheses center on the effects of the misfolded and aggregated proteins, amyloid beta and tau. The two positions are lightheartedly described as "ba-ptist" and "tau-ist" viewpoints in one scientific publication. Therein, it is suggested that "Tau-ists" believe that the tau protein abnormalities initiate the disease cascade, while "ba-ptists" believe that beta amyloid deposits are the causative factor in the disease.
The hypothesis that tau is the primary causative factor has long been grounded in the observation that deposition of amyloid plaques does not correlate well with neuron loss. A mechanism for neurotoxicity has been proposed based on the loss of microtubule-stabilizing tau protein that leads to the degradation of the cytoskeleton. However, consensus has not been reached on whether tau hyperphosphorylation precedes or is caused by the formation of the abnormal helical filament aggregates. Support for the tau hypothesis also derives from the existence of other diseases known as tauopathies in which the same protein is identifiably misfolded. However, a majority of researchers support the alternative hypothesis that amyloid is the primary causative agent.
The amyloid hypothesis is initially compelling because the gene for the amyloid beta precursor APP is located on chromosome 21, and patients with trisomy 21 - better known as Down syndrome - who thus have an extra gene copy almost universally exhibit AD-like disorders by 40 years of age. The traditional formulation of the amyloid hypothesis points to the cytotoxicity of mature aggregated amyloid fibrils, which are believed to be the toxic form of the protein responsible for disrupting the cell's calcium ion homeostasis and thus inducing apoptosis. This hypothesis is supported by the observation that higher levels of a variant of the beta amyloid protein known to form fibrils faster in vitro correlate with earlier onset and greater cognitive impairment in mouse models and with AD diagnosis in humans. However, mechanisms for the induced calcium influx, or proposals for alternative cytotoxic mechanisms, by mature fibrils are not obvious.
A more recent and broadly supported variation of the amyloid hypothesis identifies the cytotoxic species as an intermediate misfolded form of amyloid beta, neither a soluble monomer nor a mature aggregated polymer but an oligomeric species, possibly toroidal or star-shaped with a central channel that may induce apoptosis by physically piercing the cell membrane. This ion channel hypothesis postulates that oligomers of soluble, non-fibrillar Aβ form membrane ion channels allowing unregulated calcium influx into neurons. A related alternative suggests that a globular oligomer localized to dendritic processes and axons in neurons is the cytotoxic species.
Relevantly, the cytotoxic-fibril hypothesis presented a clear target for drug development: inhibit the fibrillization process. Much early development work on lead compounds has focused on this inhibition; most are also reported to reduce neurotoxicity, but the toxic-oligomer theory would imply that prevention of oligomeric assembly is the more important process or that a better target lies upstream, for example in the inhibition of APP processing to amyloid beta.
- Soluble intracellular (o)Aβ42
Two research papers published in 2009 have shown that oligomeric (o)Aβ42 (specific toxic species of Aβ), when in soluble intracellular form, acutely inhibit synaptic transmission, a pathophysiology that characterizes AD (especially in early stages), by activating casein kinase 2.
A 1994 study  showed that the isoprenoid changes in Alzheimer's disease differ from those occurring during normal aging and that this disease cannot, therefore, be regarded as a result of premature aging. During aging the human brain shows a progressive increase in levels of dolichol, a reduction in levels of ubiquinone, but relatively unchanged concentrations of cholesterol and dolichyl phosphate. In Alzheimer's disease, the situation is reversed with decreased levels of dolichol and increased levels of ubiquinone. The concentrations of dolichyl phosphate are also increased, while cholesterol remains unchanged. The increase in the sugar carrier dolichyl phosphate may reflect an increased rate of glycosylation in the diseased brain and the increase in the endogenous anti-oxidant ubiquinone an attempt to protect the brain from oxidative stress, for instance induced by lipid peroxidation. These findings appear to have been supported by a trial conducted at the Brain Sciences Institute at Swinburne University in Melbourne, Australia, reported in 2006, that confirmed certain neurocognitive effects of the polyprenol preparation Ropren identified previously in Russia  (polyprenols are metabolised into dolichols in the body).
The human brain is one of the most metabolically active organs in the body and metabolizes a large amount of glucose to produce cellular energy in the form of adenosine triphosphate (ATP). Despite its high energy demands, the brain is relatively inflexible in its ability to utilize substrates for energy production and relies almost entirely on circulating glucose for its energy needs. This dependence on glucose puts the brain at risk if the supply of glucose is interrupted, or if its ability to metabolize glucose becomes defective. If the brain is not able to produce ATP, synapses cannot be maintained and cells cannot function, ultimately leading to impaired cognition.
Imaging studies have shown decreased utilization of glucose in the brains of Alzheimer’s disease patients early in the disease, before clinical signs of cognitive impairment occur. This decrease in glucose metabolism worsens as clinical symptoms develop and the disease progresses. Studies have found a 17%-24% decline in cerebral glucose metabolism in patients with Alzheimer’s disease, compared with age-matched controls. Numerous imaging studies have since confirmed this observation.
Abnormally low rates of cerebral glucose metabolism are found in a characteristic pattern in the Alzheimer’s disease brain, particularly in the posterior cingulate, parietal, temporal, and prefrontal cortices. These brain regions are believed to control multiple aspects of memory and cognition. This metabolic pattern is reproducible and has even been proposed as a diagnostic tool for Alzheimer’s disease. Moreover, diminished cerebral glucose metabolism (DCGM) correlates with plaque density and cognitive deficits in patients with more advanced disease.
Diminished cerebral glucose metabolism (DCGM) may not be solely an artifact of brain cell loss since it occurs in asymptomatic patients at risk for Alzheimer’s disease, such as patients homozygous for the epsilon 4 variant of the apolipoprotein E gene (APOE4, a genetic risk factor for Alzheimer’s disease), as well as in inherited forms of Alzheimer’s disease. Given that DCGM occurs before other clinical and pathological changes occur, it is unlikely to be due to the gross cell loss observed in Alzheimer’s disease.
In imaging studies involving young adult APOE4 carriers, where there were no signs of cognitive impairment, diminished cerebral glucose metabolism (DCGM) was detected in the same areas of the brain as older subjects with Alzheimer’s disease. However, DCGM is not exclusive to APOE4 carriers. By the time Alzheimer’s has been diagnosed, DCGM occurs in genotypes APOE3/E4, APOE3/E3, and APOE4/E4. Thus, DCGM is a metabolic biomarker for the disease state.
- Hashimoto M, Rockenstein E, Crews L, Masliah E (2003). "Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases". Neuromolecular Med. 4 (1–2): 21–36. doi:10.1385/NMM:4:1-2:21. PMID 14528050.
- Kerr ML, Small DH (2005). "Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development". J. Neurosci. Res. 80 (2): 151–9. doi:10.1002/jnr.20408. PMID 15672415.
- Cai D, Netzer WJ, Zhong M, et al. (2006). "Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation". Proc. Natl. Acad. Sci. U.S.A. 103 (6): 1941–6. Bibcode:2006PNAS..103.1941C. doi:10.1073/pnas.0510708103. PMC 1413665. PMID 16449386.
- Danielsson J, Andersson A, Jarvet J, Gräslund A (2006). "15N relaxation study of the amyloid beta-peptide: structural propensities and persistence length". Magnetic resonance in chemistry : MRC. 44 Spec No: S114–21. doi:10.1002/mrc.1814. PMID 16826550.
- Tomaselli S, Esposito V, Vangone P, et al. (2006). "The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding". Chembiochem 7 (2): 257–67. doi:10.1002/cbic.200500223. PMID 16444756.
- Ohnishi S, Takano K (2004). "Amyloid fibrils from the viewpoint of protein folding". Cell. Mol. Life Sci. 61 (5): 511–24. doi:10.1007/s00018-003-3264-8. PMID 15004691.
- Goedert M, Klug A, Crowther RA (2006). "Tau protein, the paired helical filament and Alzheimer's disease". J. Alzheimers Dis. 9 (3 Suppl): 195–207. PMID 16914859.
- Pastorino L, Sun A, Lu PJ, et al. (2006). "The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production". Nature 440 (7083): 528–34. Bibcode:2006Natur.440..528P. doi:10.1038/nature04543. PMID 16554819.
- Lim J, Lu KP (2005). "Pinning down phosphorylated tau and tauopathies". Biochim. Biophys. Acta 1739 (2–3): 311–22. doi:10.1016/j.bbadis.2004.10.003. PMID 15615648.
- Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. (2000). "Inflammation and Alzheimer's disease". Neurobiol Aging 21 (3): 383– 421. doi:10.1016/S0197-4580(00)00124-X. PMID 10858586.
- Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N (2010). "A meta-analysis of cytokines in Alzheimer's disease". Biol Psychiat 68 (10): 930–941. doi:10.1016/j.biopsych.2010.06.012. PMID 20692646.
- Wenk GL (2003). "Neuropathologic changes in Alzheimer's disease". J Clin Psychiatry. 64 Suppl 9: 7–10. PMID 12934968.
- Tiraboschi P, Hansen L, Thal L, Corey-Bloom J (2004). "The importance of neuritic plaques and tangles to the development and evolution of AD". Neurology 62 (11): 1984–9. doi:10.1212/01.WNL.0000129697.01779.0A. PMID 15184601.
- Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH (1994). "Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital". Cereb. Cortex 4 (2): 138–50. doi:10.1093/cercor/4.2.138. PMID 8038565.
- Castellni RJ, Perry G, Smith MA (2004). "Prion disease and Alzheimer's disease: pathogenic overlap". Acta Neurobiol Exp (Wars) 64: 11–7. PMID 15190676.
- Baskys. "Receptor found that could lead to better treatments for stroke, alzheimer's disease". UCI Medical Center. Retrieved 2006-11-04.
- Shen ZX (2004). "Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease". Med. Hypotheses 63 (2): 308–21. doi:10.1016/j.mehy.2004.02.031. PMID 15236795.
- Wenk GL (2003). "Neuropathologic changes in Alzheimer's disease". The Journal of Clinical Psychiatry. 64 Suppl 9: 7–10. PMID 12934968.
- Mudher A, Lovestone S (2002). "Alzheimer's disease-do tauists and baptists finally shake hands?". Trends Neurosci. 25 (1): 22–6. doi:10.1016/S0166-2236(00)02031-2. PMID 11801334.
- Schmitz C, Rutten BP, Pielen A, et al. (1 April 2004). "Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease". Am. J. Pathol. 164 (4): 1495–502. doi:10.1016/S0002-9440(10)63235-X. PMC 1615337. PMID 15039236.
- Gray EG, Paula-Barbosa M, Roher A (1987). "Alzheimer's disease: paired helical filaments and cytomembranes". Neuropathol. Appl. Neurobiol. 13 (2): 91–110. doi:10.1111/j.1365-2990.1987.tb00174.x. PMID 3614544.
- Williams DR (2006). "Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau". Internal medicine journal 36 (10): 652–60. doi:10.1111/j.1445-5994.2006.01153.x. PMID 16958643.
- Nistor M, Don M, Parekh M, et al. (2007). "Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain". Neurobiol. Aging 28 (10): 1493–506. doi:10.1016/j.neurobiolaging.2006.06.023. PMC 3375834. PMID 16904243.
- Lott IT, Head E (2005). "Alzheimer disease and Down syndrome: factors in pathogenesis". Neurobiol. Aging 26 (3): 383–9. doi:10.1016/j.neurobiolaging.2004.08.005. PMID 15639317.
- Yankner BA, Duffy LK, Kirschner DA (1990). "Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides". Science 250 (4978): 279–82. Bibcode:1990Sci...250..279Y. doi:10.1126/science.2218531. PMID 2218531.
- Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y (2004). "Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease". Proc. Natl. Acad. Sci. U.S.A. 101 (17): 6623–8. Bibcode:2004PNAS..101.6623I. doi:10.1073/pnas.0400895101. PMC 404095. PMID 15069204.
- Gregory GC, Halliday GM (2005). "What is the dominant Abeta species in human brain tissue? A review". Neurotoxicity research 7 (1–2): 29–41. doi:10.1007/BF03033774. PMID 15639796.
- Blanchard BJ, Hiniker AE, Lu CC, Margolin Y, Yu AS, Ingram VM (2000). "Elimination of Amyloid beta Neurotoxicity". J Alzheimers Dis 2 (2): 137–149. PMID 12214104.
- Abramov AY, Canevari L, Duchen MR (2004). "Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture". Biochim. Biophys. Acta 1742 (1–3): 81–7. doi:10.1016/j.bbamcr.2004.09.006. PMID 15590058.
- Arispe, N; Rojas, E; Pollard, H B (1993-01-15). "Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum.". Proceedings of the National Academy of Sciences of the United States of America 90 (2): 567–571. ISSN 0027-8424. PMC 45704. PMID 8380642.
- Barghorn S, Nimmrich V, Striebinger A, et al. (2005). "Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease". J. Neurochem. 95 (3): 834–47. doi:10.1111/j.1471-4159.2005.03407.x. PMID 16135089.
- Kokubo H, Kayed R, Glabe CG, Yamaguchi H (2005). "Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain". Brain Res. 1031 (2): 222–8. doi:10.1016/j.brainres.2004.10.041. PMID 15649447.
- Blanchard BJ, Chen A, Rozeboom LM, Stafford KA, Weigele P, Ingram VM (2004). "Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule". Proc. Natl. Acad. Sci. U.S.A. 101 (40): 14326–32. Bibcode:2004PNAS..10114326B. doi:10.1073/pnas.0405941101. PMC 521943. PMID 15388848.
- Porat Y, Abramowitz A, Gazit E (2006). "Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism". Chem Biol Drug Des 67 (1): 27–37. doi:10.1111/j.1747-0285.2005.00318.x. PMID 16492146.
- Kanapathipillai M, Lentzen G, Sierks M, Park CB (2005). "Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer's beta-amyloid". FEBS Lett. 579 (21): 4775–80. doi:10.1016/j.febslet.2005.07.057. PMID 16098972.
- Lee KH, Shin BH, Shin KJ, Kim DJ, Yu J (2005). "A hybrid molecule that prohibits amyloid fibrils and alleviates neuronal toxicity induced by beta-amyloid (1-42)". Biochem. Biophys. Res. Commun. 328 (4): 816–23. doi:10.1016/j.bbrc.2005.01.030. PMID 15707952.
- Espeseth AS, Xu M, Huang Q, et al. (2005). "Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics". J. Biol. Chem. 280 (18): 17792–7. doi:10.1074/jbc.M414331200. PMID 15737955.
- Moreno, H.; Yu, E.; Pigino, G.; Hernandez, I.; Kim, N.; Moreira, E.; Sugimori, M.; Llinás, R. (Mar 2009). "Synaptic transmission block by presynaptic injection of oligomeric amyloid beta" (Free full text). Proceedings of the National Academy of Sciences of the United States of America 106 (14): 5901–5906. Bibcode:2009PNAS..106.5901M. doi:10.1073/pnas.0900944106. ISSN 0027-8424. PMC 2659170. PMID 19304802.
- Pigino, G.; Morfini, G.; Atagi, Y.; Deshpande, A.; Yu, C.; Jungbauer, L.; Ladu, M.; Busciglio, J.; Brady, S. (Mar 2009). "Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta". Proceedings of the National Academy of Sciences of the United States of America 106 (14): 5907–5912. Bibcode:2009PNAS..106.5907P. doi:10.1073/pnas.0901229106. ISSN 0027-8424. PMC 2667037. PMID 19321417.
- Edlund, C; Söderberg, M; Kristensson, K (1994). "Isoprenoids in aging and neurodegeneration". Neurochemistry international 25 (1): 35–8. doi:10.1016/0197-0186(94)90050-7. PMID 7950967.
- Edlund C, Söderberg M, Kristensson K (July 1994). "Isoprenoids in aging and neurodegeneration". Neurochem Int 25 (1): 35–8. doi:10.1016/0197-0186(94)90050-7. PMID 7950967.
- Sviderskii, VL; Khovanskikh, AE; Rozengart, EV; Moralev, SN; Yagodina, OV; Gorelkin, VS; Basova, IN; Kormilitsyn, BN; Nikitina, TV; Roshchin, V. I.; Sultanov, V. S. (2006). "A comparative study of the effect of the polyprenol preparation ropren from coniferous plants on the key enzymes of the cholinergic and monoaminergic types of nervous transmission". Doklady. Biochemistry and biophysics (in Russian) 408: 148–51. doi:10.1134/S1607672906030112. PMID 16913416. Lay summary.[verification needed]
- Cunnane S, Nugent S, Roy M, et al. (2011). "Brain fuel metabolism, aging, and Alzheimer's disease". Nutrition 27 (1): 3–20. doi:10.1016/j.nut.2010.07.021. PMC 3478067. PMID 21035308.
- Costantini LC, Barr LJ, Vogel JL, Henderson ST (2008). "Hypometabolism as a therapeutic target in Alzheimer's disease". BMC Neurosci 9 (Suppl 2): S16. doi:10.1186/1471-2202-9-s2-s16.
- Hoyer S (1992). "Oxidative energy metabolism in Alzheimer brain. Studies in early-onset and late-onset cases". Mol Chem Neuropathol 16 (3): 207–224. doi:10.1007/bf03159971.
- Small GW, Ercoli LM, Silverman DH, et al. (2000). "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease". Proc Natl Acad Sci U S A 97 (11): 6037–6042. Bibcode:2000PNAS...97.6037S. doi:10.1073/pnas.090106797.
- De Leon MJ, Ferris SH, George AE, et al. (1983). "Positron emission tomographic studies of aging and Alzheimer disease". Am J Neuroradiol 4 (3): 568–571.
- Meier-Ruge W, Bertoni-Freddari C, Iwangoff P (1994). "Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease". Gerontology 40 (5): 246–252. doi:10.1159/000213592. PMID 7959080.
- Reiman EM, Chen K, Alexander GE, et al. (2004). "Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia". Proc Natl Acad Sci USA 101 (1): 284–289. Bibcode:2003PNAS..101..284R. doi:10.1073/pnas.2635903100.
- Corder EH, Jelic V, Basun H, et al. (1997). "No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes". Arch Neurol 54 (3): 273–277. doi:10.1001/archneur.1997.00550150035013.
- "Diminished cerebral glucose metabolism: A key pathology in Alzheimer's disease" (PDF). Retrieved 9 October 2013.